# Angiogenic Factor Expression During Fractionated Irradiation

> **NCT02072720** · EARLY_PHASE1 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 40 (estimated)

## Conditions studied

- Primary Esophageal Carcinoma

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02072720
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02
- **Primary completion:** 2021-03
- **Final completion:** 2021-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072720, "Angiogenic Factor Expression During Fractionated Irradiation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02072720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*